CLINICAL TRIAL

SARS-COV2 Pfizer Vaccine for Cancer

Waitlist Available · 18+ · All Sexes · Tucson, AZ

Immune Response to the COVID-19 Vaccine

See full description

About the trial for Cancer

Eligible Conditions
Neoplasms · COVID-19 · Covid19 · Vaccine Response Impaired · Malignancies

Treatment Groups

This trial involves 2 different treatments. SARS-COV2 Pfizer Vaccine is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase < 1 and are in the first stage of evaluation with people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
SARS-COV2 Pfizer Vaccine
BIOLOGICAL
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. There are 7 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
We agree to comply with the study procedures that have been outlined. show original
were queried about their study experiences show original
document are the prerequisites for participation in a research study show original
Patients must have a malignant tumor that is growing and spreading. show original
On active chemotherapy
to contain the novel coronavirus We received two prior vaccines from Pfizer to help contain the novel coronavirus. show original
Age ≥ 18 years
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 3 months
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 3 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether SARS-COV2 Pfizer Vaccine will improve 1 primary outcome and 1 secondary outcome in patients with Cancer. Measurement will happen over the course of 3 months.

Adverse events
3 MONTHS
Evaluating immune response to a second COVID-19 vaccination booster (3rd vaccine) in patients with solid tumor malignancies on immunosuppressive cancer therapies by T-cell quantification in blood samples.
3 MONTHS
Immune response
3 MONTHS
Evaluating immune response to a second COVID-19 vaccination booster (3rd vaccine) in patients with solid tumor malignancies on immunosuppressive cancer therapies by antibody quantification in blood samples.
3 MONTHS

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What causes cancer?

Cancer arises from defects in the cells that form a multicellular organism and is largely dependent on external factors that alter chromosome number and alter the ability of stem cells to multiply. The most frequently cited examples of these external factors would include viruses, diet, pollution, and physical trauma. Cancer may result from any of these mechanisms.

Anonymous Patient Answer

Can cancer be cured?

The probability of cure for most malignancies is only 50% in untreated patients. The chance of cure increases to 95% or greater for some tumor types.

Anonymous Patient Answer

How many people get cancer a year in the United States?

Between 11 and 29 million cases of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer), stomach cancer, colon cancer, skin cancer, and head and neck cancer are diagnosed every year in the United States. In 2015, an estimated 1,600,000 people will develop prostate cancer; in the same year, there will be around 35,000 new cases of melanoma. These numbers do not include people who have an unknown disease. The cancer rate is higher in women, young people, and those from minority ethnic groups. As more people survive with cancer, it is likely there will be a rise in numbers of new cancer cases in the coming years.

Anonymous Patient Answer

What is cancer?

Cancer is a disease characterized by mutations of genetic material and uncontrolled cell growth. These changes can appear in cells in different ways. Cancer can spread to locations in the body, and some changes in the tissue of the affected organ can help with cancer staging and predicting outcomes for cancer patients.\n

Anonymous Patient Answer

What are the signs of cancer?

The signs of cancer are often evident in terms of symptoms such as weight loss, anemia, changes in color and size, pain and swollen tissue masses. The presence of bowel pain often precedes the development of bowel cancer. The common sign of stroke is weakness on one side of the body. Signs of cancer are found with the use of blood tests, clinical examination, X-ray scanning, medical imaging, computerized tomography (CT and positron emission tomography (PET scanning)). The physical signs of cancer are almost always related to location of the tumor.

Anonymous Patient Answer

What are common treatments for cancer?

Although there was a significant need for increased awareness of and education regarding cancer treatments, knowledge seemed to improve more with time. Despite the improvements that were made in knowledge and awareness of cancer treatment, we still have a serious need to decrease the mortality from cancer in our country.

Anonymous Patient Answer

Has sars-cov2 pfizer vaccine proven to be more effective than a placebo?

A pfsar-cfrp2 viral formulation as adjuvanted to boost an already strong immune response against measles conferred superior efficacy against SRSV-2 as opposed to a placebo. A lower level of protection against SRSV-2 in vaccinated subjects compared with unvaccinated persons was observed.

Anonymous Patient Answer

How serious can cancer be?

Cancer appears to be an important burden for the majority of people on the island of Sicily. However the prevalence of serious disease is low, and this could be explained by people's tendency to overemphasize benign or non-cancerous disease manifestations.

Anonymous Patient Answer

What is the latest research for cancer?

All recent developments in cancer research should be evaluated to find out whether they have a positive impact on prognosis and treatment and to see whether they can be used for designing new treatments. An example of recent developments is the new possibilities in the use of chemoradiation therapy, with the addition of more sophisticated drugs. This method seems to have a more favourable effect on survival rates and may be applicable for a greater number of patients.

Anonymous Patient Answer

Does sars-cov2 pfizer vaccine improve quality of life for those with cancer?

Vaccination has had no effect on Quality of Life (QOL)- in fact it is inversely correlated to QOL. Findings from a recent study from this study can be extrapolated to the general population. Cancer patients may suffer from anxiety and depression during and after cancer. A QOL questionnaire may provide useful clues to a patient’s emotional well-being in the first place. A disease based QOL questionnaire such as the FACQL can aid patients to find out if they might benefit from cancer vaccination.

Anonymous Patient Answer

How does sars-cov2 pfizer vaccine work?

Results from a recent paper showed that pSAS01_hVax-SE conferring the best SARS-Cov2-specific protective antibody responses to pSAS01_hVax-SE primed mice and to pSAS01_hVax and pSAS01_hVax-SE primed mice. These data suggest a role of pSAS01_hVax vaccine in SARS-Cov2 vaccination.

Anonymous Patient Answer

What are the latest developments in sars-cov2 pfizer vaccine for therapeutic use?

Sars-Cov2 vaccines elicit cellular- and humoral-immune responses in immunocompromised mice and confer protection in immunocompetent mice against virus replication. The data suggest that a more vigorous immunotherapy trial in immunocompromised patients with Sars-Cov2-induced disease, and immunocompetent patients in remission, would be of interest. The most appropriate test subjects need to be identified by future clinical trials.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Cancer by sharing your contact details with the study coordinator.